ABBV

AbbVie Inc

ABBV, USA

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. AbbVie Inc. has strategic partnership with OSE Immunotherapeutics. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

https://www.abbvie.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

1.73

Next Payout:

Feb 17, 2026

Yield:

3.2091 %
ABBV
stock
ABBV

Promising Dividend Stocks To Watch Today - January 21st MarketBeat

Read more →
ABBV
stock
ABBV

Price Over Earnings Overview: AbbVie - AbbVie (NYSE:ABBV) Benzinga

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$245.2222

Analyst Picks

Strong Buy

12

Buy

4

Hold

12

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

160.93

Low 50

High 10

Price to Book Ratio (P/B)

-

Very Low

-144.63

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-7.04 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

0.14 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

41.33 %

Low 5%

High 15%

Investors

* Institutions hold a combined 61.81% of the total shares of AbbVie Inc

1.

Vanguard Group Inc

(10.0364%)

since

2025/06/30

2.

BlackRock Inc

(8.3471%)

since

2025/06/30

3.

State Street Corp

(4.5299%)

since

2025/06/30

4.

JPMorgan Chase & Co

(3.2388%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(3.1422%)

since

2025/07/31

6.

Vanguard 500 Index Investor

(2.4752%)

since

2025/07/31

7.

Morgan Stanley - Brokerage Accounts

(2.3605%)

since

2025/06/30

8.

Geode Capital Management, LLC

(2.2178%)

since

2025/06/30

9.

Charles Schwab Investment Management Inc

(1.5161%)

since

2025/06/30

10.

Capital Research Global Investors

(1.4302%)

since

2025/06/30

11.

Bank of America Corp

(1.4214%)

since

2025/06/30

12.

NORGES BANK

(1.3077%)

since

2025/06/30

13.

Fidelity 500 Index

(1.2675%)

since

2025/07/31

14.

Northern Trust Corp

(1.2461%)

since

2025/06/30

15.

SPDR® S&P 500® ETF

(1.2077%)

since

2025/08/31

16.

iShares Core S&P 500 ETF

(1.2032%)

since

2025/08/31

17.

FMR Inc

(1.1888%)

since

2025/06/30

18.

Vanguard Value Index Inv

(0.8862%)

since

2025/07/31

19.

Franklin Resources Inc

(0.8552%)

since

2025/06/30

20.

UBS Asset Mgmt Americas Inc

(0.8266%)

since

2025/06/30

21.

Schwab US Dividend Equity ETF™

(0.822%)

since

2025/08/30

22.

Capital Research & Mgmt Co - Division 3

(0.7728%)

since

2025/06/30

23.

Bank of New York Mellon Corp

(0.708%)

since

2025/06/30

24.

Goldman Sachs Group Inc

(0.6888%)

since

2025/06/30

25.

The Health Care Select Sector SPDR® ETF

(0.6828%)

since

2025/08/31

26.

UBS Group AG

(0.6682%)

since

2025/06/30

27.

Legal & General Group PLC

(0.6516%)

since

2025/06/30

28.

Vanguard Institutional Index I

(0.6045%)

since

2025/07/31

29.

American Funds American Mutual A

(0.5791%)

since

2025/06/30

30.

Capital Group American Mutual Comp

(0.5791%)

since

2025/06/30

31.

Vanguard Dividend Appreciation ETF

(0.5378%)

since

2025/07/31

32.

Dimensional Fund Advisors, Inc.

(0.5376%)

since

2025/06/30

33.

State St S&P 500® Indx SL Cl III

(0.5337%)

since

2025/08/31

34.

American Funds Capital Income Bldr A

(0.4635%)

since

2025/06/30

35.

Vanguard High Dividend Yield ETF

(0.3854%)

since

2025/07/31

36.

Vanguard Institutional 500 Index Trust

(0.3818%)

since

2025/07/31

37.

Blackrock Eq Idx Fund CF

(0.378%)

since

2025/06/30

38.

iShares Russell 1000 Growth ETF

(0.3775%)

since

2025/08/31

39.

Capital Group Investment Co of Amer Comp

(0.3769%)

since

2025/06/30

40.

American Funds Invmt Co of Amer A

(0.3769%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

3.35

Latest Release

Date

2025-09-30

EPS Actual

1.86

EPS Estimate

3.27

EPS Difference

-1.41

Surprise Percent

-43.1193%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(6.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.